Cancer drug combo trial halted early after enrolling only 13 patients
Disease control
Terminated
This study tested a drug called zenocutuzumab combined with other medicines in people with two types of cancer: non-small cell lung cancer with an NRG1 gene fusion, and metastatic prostate cancer that no longer responds to hormone therapy. The trial was stopped early after enroll…
Phase: PHASE2 • Sponsor: Partner Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 20:24 UTC